Evaluation of FDG-PET/CT for the disease control assessment in pulmonary Mycobacterium avium complex (MAC) infection and chronic pulmonary aspergillosis

Takazono Takahiro0 个研究点目标入组 15 人开始时间: 2019年11月15日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Patients diagnosed with pulmonary Mycobacterium avium complex (MAC) infection based on American Thoracic Society / American Society of Infectious Diseases Guideline 2017, or patients diagnosed with chronic pulmonary aspergillosis (CPA) based on the European Society of Clinical Microbiology / European Society of Medical Mycology / European Respiratory Society 2017.
•(2) Patients who have not been treated with antimicrobial agents against pulmonary MAC infection or CPA .
•(3) Patients who are older than 20 at the time of informed consent.
•(4) Patients with written informed consent after receiving sufficient information.

•(1) Diabetic patients with poor control (more than 200 mg/dL of fasting blood glucose level).
•(2) Patients with cystic fibrosis.
•(3) Patients with active respiratory infection except for pulmonary MAC infection or CPA.
•(4) Patients with pulmonary MAC infection and CPA.
•(5) Patients with lung cancer at the time of informed consent.
•(6) Women who are currently pregnant or may be pregnant.
•(7) Patient who are judged unsuitable for this study by the investigator.

发起方

Takazono Takahiro